CC-42344 (Inhaled PB2 inhibitor)
Influenza A
Phase 1Phase 1 complete; GLP tox study complete
Key Facts
Indication
Influenza A
Phase
Phase 1
Status
Phase 1 complete; GLP tox study complete
Company
About Cocrystal Pharma
Cocrystal Pharma is focused on discovering and developing first- and best-in-class antiviral drugs that target the viral replication machinery. The company's unique technology platform, guided by Nobel laureate Dr. Roger Kornberg, enables the efficient design of inhibitors against proteases and polymerases. With multiple programs advancing through clinical trials, including oral and inhaled candidates for influenza and a dual coronavirus-norovirus protease inhibitor, Cocrystal aims to address significant unmet needs in antiviral treatment with drugs designed to be safe, convenient, and resistance-resistant.
View full company profileTherapeutic Areas
Other Influenza A Drugs
| Drug | Company | Phase |
|---|---|---|
| CC-42344 (Oral PB2 inhibitor) | Cocrystal Pharma | Phase 2 |